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Abstract: In recent years, several European countries reported cases of imported chikungunya 
infection. We present the first imported clinically manifested chikungunya fever in Croatia. A 
27-year-old woman returned to Croatia on 21 March 2016, after she stayed in Costa Rica for two 
months where she had noticed a mosquito bite on her left forearm. Five days after the mosquito bite 
she developed severe arthralgias, fever and erythematous papular rash. In next few days symptoms 
gradually subsided. After ten days she felt better, but arthralgias re-appeared accompanied with 
morning stiffness. Two weeks after the onset of the disease she visited the infectious diseases out-
patient department. The physical examination revealed rash on the trunk, extremities, palms and 
soles. Laboratory findings showed slightly elevated liver transaminases. Serological tests performed 
on day 20 after disease onset showed a high titer of chikungunya virus (CHIKV) IgM and IgG 
antibodies which indicated CHIKV infection. CHIKV-RNA was not detected. Serology to dengue 
and Zika virus was negative. The patient was treated with nonsteroid anti-inflammatory drugs and 
paracetamol. Her symptoms ameliorated, however, three months later she still complaint of arthral-
gias. The presented case highlights the need for inclusion of CHIKV in the differential diagnosis 
of arthralgia in all travelers returning from countries with documented CHIKV transmission.
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Introduction
Chikungunya fever is a mosquito-borne emerging viral disease caused by chikungunya 
virus (CHIKV), which belongs to the genus Alphavirus of the family Togaviridae. It 
is endemic in many parts of Africa and Asia where seroprevalence rates reach 75%.1 
In Africa, the virus maintains a sylvatic cycle between nonhuman primates and forest-
dwelling mosquitoes, while in Asia transmission of CHIKV occurs in an urban cycle 
involving humans and Aedes spp. mosquitoes (Ae. aegypti, Ae. albopictus).2 Typical 
clinical symptoms of chikungunya include fever, headache, myalgia, rash, and arthralgia. 
The symptoms, particularly joint pain, can be severe and long lasting in many patients.3
In many European countries, imported cases of chikungunya were repeatedly 
reported.4–7 First, autochthonous CHIKV cases were reported during the 2007 out-
break and involved more than 200 cases in the Ravenna Province, Italy.8,9 In 2014, 
an outbreak including 12 CHIKV cases occurred in Montpelier, France.10 In Croatia, 
CHIKV antibodies were sporadically detected in travelers from endemic areas. A 
seroepidemiological study conducted during 2011–2012 showed that 0.9% inhabitants 
of the Croatian littoral are seropositive to CHIKV.11 We report the first detection of an 
imported, clinically manifested case of chikungunya fever in Croatia.
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Case report
Clinical presentation and laboratory 
findings
On March 26, 2016, a 27-year-old woman visited the infec-
tious diseases outpatient department because of persistent 
arthralgias and rash. She works as a stewardess on a cruise ship 
and she stayed in Costa Rica for 2 months where she developed 
symptoms; then she returned to Croatia on March 21. Six 
months before this illness, she was vaccinated against yellow 
fever. She remembered a mosquito bite on her left forearm 
because she noticed a little hematoma around the indurated 
papule which she had not experienced after earlier mosquito 
bites. Five days after the mosquito bite, on the first day of her 
disease, she felt symmetrical arthralgias in her ankles, knees, 
wrists, and elbows but also in small joints of her hands and 
feet. The third day, she developed high fever up to 38.5°C with 
chills. Her arthralgias deteriorated, so she could hardly walk. 
On the fifth day of her illness, an itchy rash appeared on her 
trunk, and the next day it extended to her face, extremities, 
as well as palms and soles. The erythematous papular rash 
subsided in the next 2 days. At the same time, she became 
afebrile, while arthralgias remained up to the tenth day of 
her illness after which she was feeling well, but exhausted. 
During the acute phase of her illness, she had nausea and she 
had a few loose stools too. Ten days after she had recovered, 
severe arthralgias in her ankles, elbows, right shoulder, and 
in the small joints of hands and feet reappeared. She also 
complained about morning stiffness lasting for 10–30 min.
On the initial visit (day 15 after the disease onset), the 
physical examination was normal except for rash on the trunk, 
extremities, palms, and soles (Figure 1). Routine laboratory 
tests were normal, except for slightly elevated liver trans-
aminases, erythrocytes 4.35×1012/L (reference range [RR]: 
3.86–5.08), leukocytes 8.4×109/L (RR: 83.4–9.7), lympho-
cytes 21.5% (RR: 20–46), C-reactive protein 1.3 mg/L (<5), 
platelets 219×109/L (RR: 158–424), BUN 5.4 mmol/L (RR: 
2.8–8.3), creatinine 70 µmol/L (RR: 63–107), aspartate ami-
notransferase 32 U/L (RR: 8–30), alanine aminotransferase 
51 U/L (RR: 10–36), γ-glutamyl transferase 21 U/L (RR: 
9–35), and lactate dehydrogenase 196 U/L (RR: 25–241).
According to the case definition proposed by the interna-
tional chikungunya expert group (2015), which distinguishes 
4 chikungunya case categories; acute clinical case, atypical 
case, severe acute case, and suspected and/or confirmed 
chronic case;12 our patient was classified as a confirmed 
chronic chikungunya case. The patient was treated with non-
steroidal anti-inflammatory drugs and paracetamol. She was 
regularly followed up during the next few months in order to 
treat her arthralgias and also to observe the progress of her 
illness. Her symptoms ameliorated, but 3 months later she 
still reports arthralgias.
Virological results
Due to similar geographical distribution and clinical symp-
toms, the serum sample (taken on day 20) was initially tested 
for CHIKV IgM/IgG antibodies, using indirect immunofluo-
rescent assay (IFA; Euroimmun, Lübeck, Germany) as well as 
Zika virus (ZIKV) IgM/IgG and dengue virus (DENV) IgM/
IgG antibodies using enzyme-linked immunosorbent assay 
(ELISA; Euroimmun). To exclude potential cross reactivity 
with other arboviruses, the sample was additionally tested 
for West Nile virus (WNV) and Usutu virus (USUV) anti-
bodies using ELISA (Euroimmun), as well as yellow fever 
virus (YFV), Japanese encephalitis virus (JEV), and tick-
borne encephalitis virus (TBEV) using IFA (Euroimmun). 
Serology results are presented in Table 1. CHIKV IgM and 
IgG antibodies were detected with titre 1:100 and 1:10,000, 
respectively (Figure 2). In addition, postvaccinal YFV IgG 
antibodies were found (titer 100). There was no cross reactiv-
ity with other tested arboviruses.
Figure 1 Rash on patient with chikungunya infection.
Notes: (A) Trunk, (B) foot, and (C) palm.
A B C
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In addition, the sample was tested for the presence of 
CHIKV RNA using a qualitative real-time reverse transcrip-
tase-polymerase chain reaction (RT-PCR) according to the 
protocol described by Smith et al.13 For nucleic acid isola-
tion, an automated system QIAxtractor (QIAGEN, Hilden, 
Germany) was used. Real-time RT-PCR was performed using 
a single-tube RT-PCR test kit (Invitrogen SuperScript™III 
Platinum® One-Step Qualitative Kit; Carlsbad, CA, USA). 
The amplification and detection were performed with 7500 
Real Time PCR System (Applied Biosystems, Foster City, 
CA, USA). The test tube contained a 25-µL reaction mixture 
which included 5 µL of isolated RNA, 0.2 µM forward primer 
(CCGAAAGGAAACTTCAAAGCAACT), 0.2 µM reverse 
primer (CAGATGCCCGCCATTATTGAT), and 0.1 µM probe 
(FAM-GGGAGGTGGAGCATG-MGB). The reaction mixture 
was exposed to a 30 min 50°C reverse transcription step, 2 min 
of Taq activation at 95°C, and 50 cycles consisting of 95°C for 
15 sec and 55°C for 32 sec. No CHIKV RNA was found in the 
tested sample. Sensitivity of the RT-PCR is reported to be high 
(0.3 plaque-forming units; PFU/mL), as is specificity (no cross 
reactivity with the most common alphaviruses that contained a 
minimum of 3 log
10
 PFU of heterologous viral RNA).13
Discussion
After a bite from an infected mosquito, CHIKV rapidly 
spreads in the body eventually causing acute illness. It is 
known that up to 18% of infected patients, usually those 
younger than 25 years, are asymptomatic.14 After the resolu-
tion of the acute illness symptoms, myalgias and arthralgias 
may persist for weeks, months, and even years. The propor-
tion of patients suffering from the chronic form of disease that 
can be attributed to CHIKV infection varies between stud-
ies. In Singapore, 13% of patients had arthralgias 3 months 
after the acute phase, while 49% of patients from India had 
arthralgia 10 months after disease onset. After the outbreak 
of chikungunya in Italy, 70% of patients reported persistent 
arthralgias after six months and after 12 months, and chronic 
symptoms were present in 32% of patients.15 Severe arthralgia 
with morning stiffness was the most prominent symptom in 
our patient, too. Three months after disease onset, she still 
reported arthralgia.
Lymphopenia and thrombocytopenia are the most com-
monly detected pathologic laboratory findings associated 
with CHIKV infection. In the Reunion Island outbreak, 
lymphopenia was observed in 79% and moderate thrombocy-
topenia in 40%–50% of chikungunya patients.16 In our case, 
the only abnormal laboratory findings were slightly elevated 
liver enzymes, a finding that has been less commonly reported 
during chikungunya fever. Lymphocyte count was normal, but 
at the lower limit of the normal range. Similarly, leukopenia 
and thrombocytopenia were uncommon in imported CHIKV 
cases in Italy during 2006.17
Knowledge about the time period between the infec-
tion and the onset of symptoms is crucial as it can improve 
measures to prevent spreading of vector-borne infections. 
The incubation period in our patient was exactly 5 days, as 
she recalls the day when she had the mosquito bite. CHIKV 
viremia is usually short-lived (5 to 6 days), and so RT-PCR 
is most sensitive when performed within a week after disease 
onset. However, a study from Indonesia showed that duration 
Table 1 Serology results of patient with chikungunya infection
Virus ELISA IgM 
(ratio)a
ELISA IgG 
(RU/mL)b
IFA IgM 
(titer)
IFA IgG 
(titer)
Chikungunya ND ND 100 10,000
Dengue Negative (0.69) Negative (3) ND ND
Zika Negative (0.28) Negative (<2) ND ND
West Nile Negative (0.57) Negative (5) Negative Negative
Usutu ND Negative (<2) ND ND
Japanese 
encephalitis
ND ND Negative Negative
Yellow fever ND ND Negative 100
Tick-borne 
encephalitis
ND ND Negative Negative
Notes: aIgM ratio <0.8 negative, 0.8–1.1 borderline, >1.1 positive; bIgG RU <16 
negative, 16–22 borderline, >22 positive.
Abbreviation: ELISA, enzyme-linked immunosorbent assay; IFA, indirect 
immunofluorescence assay; ND, not determined; RU, relative unit.
Figure 2 Indirect immunofluorescence assay of blood sample from a patient with chikungunya infection. (A) Dilution 1:100; (B) dilution 1:1,000; (C) dilution 1:10,000; and 
(D) negative control.
A B C D
CHIKV IgG
1:100 1:1,000 1:10,000 Negative
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of viremia during chikungunya was extended as early as 6 
days prior until 13 days post-onset of fever.18 This observation 
suggests the possibility that our patient was viremic when she 
returned to Croatia and that she could have been a CHIKV 
reservoir, representing the possible threat for transmission 
and spreading of CHIKV, since one of the main vector, Ae. 
albopictus, is established in this area.11 RT-PCR was per-
formed to confirm the presence of viremia; however, CHIKV 
RNA was not detected. Since the sample was collected in the 
post-acute phase and both CHIKV IgM and IgG antibodies 
were documented, the probability to detect viral RNA was low.
Serology is the most commonly used method for diagno-
sis of arboviral infections. Due to similar clinical symptoms 
and possible coinfections,19 CHIKV, DENV, and ZIKV were 
included in differential diagnosis in our patient. High titer of 
CHIKV IgM and IgG antibodies as well as negative DENV 
and ZIKV serology indicated CHIKV infection.
In recent years, the risk of CHIKV emergence in Europe 
is increasing, as imported cases of chikungunya are con-
tinuously reported. Any country where Aedes mosquito is 
present represents a potential area for future chikungunya 
outbreaks. Climate changes modeling and Ae. albopictus 
distribution maps showed that hot spots for establishment 
of this mosquito species in Europe are southern France, the 
northern and northeastern coasts of Spain, Portugal, Italy, the 
eastern coasts of the Adriatic, and western Turkey. During 
the last 2 decades, mosquito climate suitability has signifi-
cantly increased over the southern UK, northern France, the 
Benelux, parts of Germany, Italy, Sicily, Slovenia, Croatia, 
and Bosnia and Herzegovina.20 It has been observed that the 
elimination of invasive mosquito species such as Ae. albop-
ictus is extremely difficult, if possible at all. Considering 
the intensive airline travel between Europe and other parts 
of the world, it is almost just a question of when chikun-
gunya will emerge as an autochthonous disease in Europe. 
In Croatia, this situation already happened with dengue in 
2010;21 therefore, there is a great possibility that the same 
scenario will happen with CHIKV, since a competent vector 
Ae. albopictus is present in Croatia. Control measures should 
be regularly performed, particularly in areas with established 
Ae. albopictus population.
Conclusion
Detection of imported chikungunya fever in Croatia high-
lights the need for clinicians to consider chikungunya in the 
differential diagnosis of arthralgia in all persons returning 
from areas where CHIKV transmission is documented.
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